Protara Therapeutics Inc (TARA)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $146.54M
Last updated: Nov 17, 2026 at 4:10 PM ET
Protara Therapeutics Inc (TARA) Stock Chart
Protara Therapeutics (TARA) has a latest price of $2.32 on Nov 17, 2026, 70.3% below its 52-week high of $7.82. Its price fell 57.9% over the past 12 months. The month-end price fell 99.4% over the 10 years through Oct 2026, a compound annual decline of 39.8%.
Price Chart
From Oct 2016 to Oct 2026, its highest month-end close was $408.00 in Nov 2016 and its lowest $1.25 in Oct 2023, adjusted for splits.
Month-end closes, adjusted for splits. Dividends are not included.
Chart TARA with Advanced Charting
Daily candlesticks, valuation multiples, side-by-side comparisons and drawings for TARA.
Free with a GNG account. No credit card.
Price Performance
Over the past 3 months the price fell 41.4%, and over 6 months it fell 46.5%. The month-end price rose 99.2% over the 3 years through Oct 2026, a compound annual rate of 25.8%.
| Period | Change |
|---|---|
| 1 month | -0.4% |
| 3 months | -41.4% |
| 6 months | -46.5% |
| 12 months | -57.9% |
| 12 months, with dividends | -57.9% |
| Period | Change | Per year |
|---|---|---|
| 3 years | +99.2% | +25.8% |
| 5 years | -64.2% | -18.6% |
| 10 years | -99.4% | -39.8% |
Price by Year
Its best calendar year was 2024, when the price rose 181.6%, and its weakest was 2019, when it fell 81.9%.
| Year | Close | Change |
|---|---|---|
| 2026 through Oct 2026 | $2.48 | -53.5% |
| 2025 | $5.33 | +0.9% |
| 2024 | $5.28 | +181.6% |
| 2023 | $1.88 | -30.0% |
| 2022 | $2.68 | -60.3% |
| 2021 | $6.75 | -72.1% |
| 2020 | $24.21 | +47.6% |
| 2019 | $16.40 | -81.9% |
| 2018 | $90.80 | +19.5% |
| 2017 | $76.00 | 0.0% |
Trading Range
The price is 17.9% below its 50-day average of $2.83 and 46.4% below its 200-day average of $4.33.
| Measure | Value | Price vs |
|---|---|---|
| Latest price (Nov 17, 2026) | $2.32 | |
| 52-week high | $7.82 | -70.3% |
| 52-week low | $2.09 | +11.0% |
| 50-day average | $2.83 | -17.9% |
| 200-day average | $4.33 | -46.4% |
Price Risk
Over 3 years, its largest fall from a peak was 71.8%.
| Measure | Value |
|---|---|
| 1-year beta | 1.32 |
| Largest fall, 1 year | -71.8% |
| Largest fall, 3 years | -71.8% |
Advanced Charting Features
Advanced Charting is free with a GNG account, and signed-in members get it in place of the price chart above.
- Valuation multiples. Daily P/E, price to sales, cash flow and book value, PEG and PEGY, drawn behind the price wherever the company's data supports them.
- Price charts and drawings. Candlestick, OHLC, line and area charts with volume and earnings, dividend and split markers, plus trend lines, levels and notes kept in your account.
- Side-by-side compare. Two stocks next to each other on one metric and time span, each chart with its own price scale.
- Projections and saved views. Pick a start and an end point to see the price return, dividends and total return between them, and save views to open later.
Frequently Asked Questions About TARA
What is TARA's 1-year price change?
Protara Therapeutics's price fell 57.9% over the past 12 months. With dividends included, the 12-month total return was -57.9%.
What is TARA's 5-year price change?
Protara Therapeutics's month-end price fell 64.2% over the 5 years through Oct 2026, a compound annual decline of 18.6%. These figures leave out dividends.
What is TARA's 52-week high and low?
Protara Therapeutics's 52-week high is $7.82 and its 52-week low is $2.09. Its latest price of $2.32 on Nov 17, 2026 is 70.3% below the high.
What is TARA's beta?
Protara Therapeutics's 1-year beta against the S&P 500 is 1.32, so its price has moved more than the market over the past year. Its largest fall from a peak over the past year was 71.8%.
Is the TARA chart free?
Yes. Advanced Charting for TARA is free with a GNG account, and no credit card is needed. It adds daily candlestick and line charts with volume, valuation multiples, side-by-side comparisons, drawings and saved views.
TARA pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Competitors